Targeting the epidermal growth factor receptor

Por El-Rayes, B F, LoRusso, P M
Publicado em 2004

Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma

Por Naing, A, LoRusso, P, Fu, S, Hong, D, Chen, H X, Doyle, L A, Phan, A T, Habra, M A, Kurzrock, R
Publicado em 2013

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

Por Schwartz, G K, LoRusso, P M, Dickson, M A, Randolph, S S, Shaik, M N, Wilner, K D, Courtney, R, O'Dwyer, P J
Publicado em 2011

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapi...

Por Macaulay, V. M., Middleton, M. R., Protheroe, A. S., Tolcher, A., Dieras, V., Sessa, C., Bahleda, R., Blay, J.-Y., LoRusso, P., Mery-Mignard, D., Soria, J.-C.
Publicado em 2013

Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced...

Por Garrett, C R, Siu, L L, El-Khoueiry, A, Buter, J, Rocha-Lima, C M, Marshall, J, LoRusso, P, Major, P, Chemidlin, J, Mokliatchouk, O, Velasquez, L, Hayes, W, Feltquate, D, Syed, S, Ford, S, Kollia, G, Galbraith, S, Nuyten, D S A
Publicado em 2011